CONDENSED CONSOLIDATED BALANCE SHEETS(USD ($))	Jun. 30, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 147,264,448	$ 129,609,317
Accounts receivable, net of allowance for doubtful accounts	17,821,673	11,206,244
Inventories	80,907,813	75,679,173
Prepayments and other current assets	5,503,155	5,664,919
Total Current Assets	251,497,089	222,159,653
Property, plant and equipment, net	62,337,422	51,325,177
Intangible assets, net	3,104,210	3,541,582
Land use rights, net	6,373,176	5,818,709
Deposits related to land use rights	16,669,167	14,752,574
Restricted cash	2,786,502	2,912,145
Equity method investment	10,937,307	10,537,310
Total Assets	353,704,873	311,047,150
Current liabilities
Short-term bank loans	4,860,000	7,935,000
Accounts payable	3,018,095	2,908,624
Due to related parties	4,055,925	4,081,624
Other payables and accrued expenses	25,895,823	25,423,349
Advance from customers	2,381,166	2,857,420
Income tax payable	3,333,141	4,513,075
Total Current Liabilities	43,544,150	47,719,092
Deferred income	2,972,700	2,912,145
Other liabilities	3,410,801	2,996,749
Total Liabilities	49,927,651	53,627,986
Stockholders' Equity
Common stock: par value $0.0001; 100,000,000 shares authorized; 26,952,945 and 26,629,615 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	2,695	2,663
Additional paid-in capital	67,303,915	62,251,731
Retained earnings	150,220,786	119,143,000
Accumulated other comprehensive income	18,826,850	14,072,322
Total equity attributable to China Biologic Products, Inc.	236,354,246	195,469,716
Noncontrolling interest	67,422,976	61,949,448
Total Stockholders’ Equity	303,777,222	257,419,164
Commitments and contingencies
Total Liabilities and Stockholders’ Equity	$ 353,704,873	$ 311,047,150